Acute respiratory infections in children: etiopathogenetic therapeutic options today

Summary: The article reveals current data on the epidemiology of acute respiratory infections and antiviral defense mechanisms with regard to the anatomical and physiological characteristics of children's immune system and options for etiopathogenetic therapy. The focus is on the antiviral and immunomodulatory drug pranobex inosine (Isoprinosine), with data from literature on the use of inosine pranobex in children with respiratory infections. The efficacy and safety of inosine pranobex (Isopinosine) in pediatric practice is demonstrated.